AXLRx Book a callCommission

Mid Specialty · Company profile

Travere

Commission a Travere report

By therapy area

Therapy area All areas Rare Disease

AXLRx reports featuring Travere

CI · Rare Disease · CI Team · Launch Lead · Market Access US IgA Nephropathy Competitive Intelligence From zero disease-specific drugs to five in three years: how endothelin, complement and APRIL inhibitors are redrawing the IgAN market. US · In-Market · Read report → DL · Rare Disease · CI Team · Launch Lead US IgA Nephropathy Disease Landscape US IgA nephropathy has shifted from RAS-blockade supportive care to five disease-modifying therapies. This maps the epidemiology and the biopsy-and-proteinuria diagnostic gate that still controls who reaches them. US · In-Market · Read report → P&HTA · Rare Disease · Market Access · Medical Affairs US IgA Nephropathy Payer & HTA US payers gate the five FDA-approved IgAN therapies on biopsy, proteinuria and RAS-blockade step-through. The Filspari REMS, Part D routing and the ICER 2026 assessment set the rest of the access path. US · In-Market · Read report →